UCL Institute of Cardiovascular Science
- Myocardial disease
- Structural heart disease
- Vascular disease
- Cardiovascular genetics
- Regenerative medicine
- Genetic epidemiology and translational cardiovascular genomics
- Preventions and outcomes
- News & events
- For staff
- Contact us
Professor Andrew Taylor
- Mr TY Hsia – Consultant Paediatric Cardiac Surgeon
- Dr Silvia Schievano – Royal Academy of Engineering/ EPSRC Post-doctoral Fellow in Biomedical Engineering
- Dr Giovanni Biglino – Foundation Leducq Post-doctoral Fellow
- Mr Rod Jones – Research Radiographer
- Ms Wendy Norman – Research Radiographer
- Mr Claudio Capelli – BHF PhD Student
- Ms Daria Cosentino – PhD Student
- Dr Catriona Barker – Foundation Leducq Clinical PhD Student
- Dr Hopewell Ntsinjana – Clinical PhD Student
- Dr Michael Quail – BHF Clinical Research Training Fellow – PhD
- Dr Christopher Critoph – BHF Clinical Research Fellow
- Dr Dan Knight – BHF Clinical Research Fellow – MD (shared with Dr. Joseph Davar)
Professor Andrew Taylor
Centre for Cardiovascular MR
Great Ormond Street Hospital for Children
Great Ormond Street
London WC1N 3JH
Research Manager - Steven Kimberly
Tel +44 (0)20 7405 9200 ext 5616
Computational and structural imaging
Our research investigates the mechanisms underlying regulation of blood vessel formation and function of the mature cardiovascular system by Vascular Endothelial Growth Factor (VEGF) and other growth factors. A major focus of this work is to identify the signalling pathways and receptors involved in these biological functions of VEGF, communication between them and how they integrate into physiologically relevant networks. We are pursuing these aims through in vivo analysis in disease and genetic models, combined with imaging and biochemical studies in cell culture. Another important aspect of our work is the development of new therapeutic approaches designed either to promote or to inhibit VEGF functions dependent on the disease context. Research in our centre is supported by major programme grant funding from the British Heart Foundation, and additional funding from the European Commission (EC), and Biotechnology and Biological Sciences Research Council (BBSRC).
Key research activities
In congenital heart disease, predicting how patients will respond to treatments such as surgery, catheter interventions, and pharmacology, as well as determining which treatments to use and when to use them, can be difficult due to small patient numbers and limited outcome data. Furthermore, we are interested in specific outcomes for individual patients, for example a 40-year old who may have undergone an intervention as a neonate. Unfortunately, collecting robust data over a 40-year period is fraught with problems, not least of all, over this long time period treatment options will enviably change. Therefore, information from our current patients may not be useful as we would like for neonates being operated on today.
Our new approach is to use investigative data now being provided by imaging, pressure monitoring, clinical observations and exercise to build representative models of the heart and cardiovascular system. These models can be tested and validated by using surgical/percutaneous interventions, or exercise/pharmacological stimulations. The utility of these models is that we can begin to predict which operation will provide the optimal result for any individual patient within in a range of congenital heart disease such as Tetralogy of Fallot or single ventricle; as well as acquired heart diseases such as hypertrophic cardiomyopathy.
Over the last 7 years, we have used cross-sectional imaging to assess how patients respond to treatments from a physiological perspective, in particular before, during, and after percutaneous device implantation (PPVI) and surgery. The research has had a direct impact on patient selection for PPVI and surgery, and continues to improve the safety of the technique. Our research has shown an increased success rate of PPVI following the introduction of MRI cross-sectional imaging into the assessment protocol.
In addition, we are using imaging techniques to develop the next generation of PPVI devices and are now in the process of developing imaging strategies for other forms of congenital heart disease, aortic and mitral valve disease, and carcinoid disease.
There has always been a very sensitive issue for parents when autopsy is required for foetuses, neonates, or infants. Our preliminary data in this area suggests that for certain cases imaging may be able to replace conventional autopsy. The data we have collected from over 400 cases may lead to a change UK policy for autopsy assessment in the future.
In 2009, we reported the first ever whole-body imaging of a human at 9.4T (The Lancet 2009; 374:467) and developed mechanisms whereby parents of children who are referred for forensic examination (HM Coroners’ examinations in the UK) are able to volunteer their child to take part in the research (The Lancet 2008; 372:715). This was previously not possible in the UK, and may now provide a fundamental change to the way that parents can now be approached. Future work in this area will focus on integrating post-mortem (PM) MRI into clinical PM practice throughout the UK, and expand the use of high-resolution MRI in this field.